Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective
How can we use tests to optimise ovarian cancer treatment with PARP-inhibitor? In this MEDtalk, Kristina Yvonne Kathe Lindemann, Associate Professor – Department of Gynaecological Oncology, Oslo University Hospital, gives her perspective on how we can secure which patients benefit from the treatment.
